Bristol-Myers Squibb Company
ERBITUX® Supplemental Biologics License Application for Advanced Non-Small Cell Lung Cancer Submitted to U.S. Food and Drug Administration
Published in Respiratory Therapeutics Week, December 22nd, 2008
ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company (NYSE: LLY), and Bristol-Myers Squibb Company (NYSE: BMY) announced that they have submitted an application to the U.S. Food and Drug Administration (FDA) to broaden the use of ERBITUX® (cetuximab) to include first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) in combination with platinum-based chemotherapy (cisplatin/vinorelbine). Bristol-Myers Squibb is ImClone’s partner for ERBITUX in North America. The FDA will notify ImClone whether it has accepted the submission for review in February 2009. “This submission reflects our continued efforts to maximize the potential of ERBITUX by broadening...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Respiratory Therapeutics Week
More Articles from Respiratory Therapeutics Week
- NIH/National Heart, Lung and Blood Institute
Researchers find new genetic target for sickle cell disease therapy - Angiotensins
Research conducted at B.R. Haymore and co-authors has provided new information about angiotensins - Asthma
Research from P. Chervinsky and co-authors yields new data on asthma - Asthma
Research from Stanford University in the area of asthma published - Community-Acquired
Research from P.G. Ambrose and co-researchers yields new findings on community-acquired - HIV/AIDS Co-Infection
Researchers from University of Pennsylvania, Medical Department detail findings in HIV/AIDS co-infection - More from this issue of Respiratory Therapeutics Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
